Navigation Links
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
Date:7/26/2013

LONDON and CAMBRIDGE, England, July 26, 2013 /PRNewswire/ --

PolyTherics receives new investment to accelerate growth

PolyTherics Limited ("PolyTherics") announces that it has merged with Antitope Limited ("Antitope"), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with an extensive suite of services and technologies to enable the development of better biopharmaceuticals.

PolyTherics is issuing new shares up to an aggregate value of £13.5 million to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations (AIM: IVO) led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.

The enlarged PolyTherics group will leverage its combined portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. The combined portfolio will include conjugation technologies to produce more stable and homogeneous antibody drug conjugates, technologies to optimise the pharmacokinetics of biologics, technologies for immunogenicity screening, technologies to re-engineer antibodies and proteins to reduce their immunogenicity, and cell line development technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world's top companies.

Dr John Burt will continue as CEO of PolyTherics and Antitope will operate as a wholly owned subsidiary of the PolyTherics group. Dr Matthew Baker will continue as Chief Scientific Officer for Antitope and the company will retain its base, management and operational structure at the Babraham Research Campus, near Cambridge.    

The expanded offering will provide the PolyTherics group with a broad technology platform for growth and a solid financial base with sustainable revenue streams over the short-, medium- and longer-term. Growing revenues are derived from the services offered by Antitope and feasibility studies undertaken by PolyTherics and from pre-defined milestone payments under licence agreements for the group's conjugation and de-immunisation technologies. These licences also have the potential to provide future royalties on a portfolio of products which utilise the group's proprietary technologies.

Dr John Burt, CEO of PolyTherics, said: "The combination of PolyTherics and Antitope is a significant strategic step, immediately broadening our business and accelerating our growth. We look forward to building PolyTherics into a leading global provider of technologies that enable the development of better biopharmaceuticals."

Dr Matthew Baker, CEO and CSO of Antitope, said: "The combination of Antitope with PolyTherics provides an excellent opportunity for us to expand and grow our offering to our existing partners. The combined company will have critical mass in terms of technologies, skills and resources and will enable us to leverage the full potential of our antibody engineering and deimmunisation platforms. We are delighted to become part of the PolyTherics group and believe this move will enable us to support growing demand for our technologies from the global biopharma industry."

About PolyTherics

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.

PolyTherics' portfolio includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals, including ThioBridge™ for more stable and homogeneous antibody drug conjugates, TheraPEG™, CyPEG™, HiPEG™ and PolyPEG™ for optimisation of the pharmacokinetics of biologics  and GlycoPol™ for targeted delivery.

The PolyTherics group will provide immunogenicity testing, antibody humanisation and protein re-engineering technologies through its Antitope subsidiary, including EpiScreen™, Composite Human Antibody™, Composite Protein™ and Composite CHO™. These technologies have been used to develop several therapeutic antibody candidates that are advancing through clinical trials. The group provides its services and technologies to an international client base that includes many of the world's leading biotechnology and pharmaceutical companies.

PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individual's funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.

http://www.polytherics.com

http://www.antitope.co.uk

For more information contact:

John Burt, PolyTherics
Tel.: +44(0)20-7691-3580
Email: john.burt@polytherics.com

Matthew Baker, Antitope
Tel.: +44(0)1223-496190
Email:  matthew.baker@antitope.co.uk

Mark Swallow, Sita Shah, Chris Gardner
Citigate Dewe Rogerson
Tel.: +44(0)20-7282-2948/1052/2995
Email: mark.swallow@citigatedr.co.uk


'/>"/>
SOURCE PolyTherics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu's New MALDI-7090 TOF-TOF Mass Spectrometer Combines High Throughput, High Resolution and High Energy for the Ultimate in Tandem MS Capabilities
2. FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice
3. Fantastic flash memory combines graphene and molybdenite
4. Motus Brings a Whole New Dimension to the NFL Combine Training Program at IMG Academy
5. New Informatics and Bioimaging Center combines resources, expertise from UMD, UMB
6. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. NYSCF scientists create personalized bone substitutes from skin cells
9. American Management Association Teams With Biogen Idec To Create Life Skills Workshops For People Living With Hemophilia
10. Data Spectacles Create Rosy Tint
11. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):